Fig. 5

KHDRBS1 mediates suppression of F1F3-induced IL-18 secretion in vivo. (A) Schematic of the NSG mouse therapeutic model used for evaluating F1F3 treatment efficacy. (B–C) Tumour weight and size measurements of xenografts from treated and control groups. (D) Comparison of tumour weights derived from wild-type HeLa cells and KHDRBS1-KO HeLa cells. (E) Hematoxylin and eosin (H&E) staining of tumour tissues illustrating histopathological differences between groups. (B–E) Data are presented as mean ± SEM. Statistical significance was assessed by one-way ANOVA: ns (not significant), *P < 0.05, ****P < 0.0001.